PRINCETON, N.J., Nov. 21, 2016 /PRNewswire/ -- On Friday, November 18, 2016, Probuphine® was named a gold award winner at the 13th annual Stevie® Awards for Women in Business in the category of "Best New Product or Service of the Year." Braeburn Pharmaceuticals' President and CEO, Behshad Sheldon, was also selected as a bronze award winner in the category of "Best Female Executive of the Year." Both awards were in the Consumer Products category.
Sheldon is committed to bringing innovative, new treatment options to treat chronic diseases shrouded in stigma, such as opioid dependence, pain and schizophrenia. Braeburn is focused on serving patients suffering from health conditions where there has been little innovation in recent years.
Gold award winner Probuphine is a six-month buprenorphine implant for the maintenance treatment of opioid addiction. Under Sheldon's leadership, this product advanced through clinical development and received FDA approval for commercialization in May 2016. Braeburn is also developing six late-stage product candidates and two earlier-stage product candidates, all of which are either injectables or implants.
"Braeburn's mission is to bring innovative and transformative treatments to underserved patients as quickly as possible," said Sheldon. "Our company has a robust pipeline of treatments for patients who are often neglected and stigmatized by society, yet who deserve the same level of innovation that is dedicated to other chronic diseases. We are honored to be recognized as we work tirelessly to fulfill our vision."
The awards were presented Friday, November 18 at the Annual Stevie Awards dinner in New York City. The event featured nominees from the U.S. and around the world, including leaders, entrepreneurs, employees and their companies.
"Judges were impressed with the quality of each nomination that qualified as a Stevie Finalist. The competition has grown each year because there are so many high-achieving women all over the world, who serve as an inspiration to those who would like to start, grow or lead a business," said Michael Gallagher, founder and president of the Stevie Awards. "It is always a privilege to recognize such outstanding women."
For more information about Braeburn Pharmaceuticals, please visit us online at BraeburnPharmaceuticals.com.
About Stevie Awards
The Stevie Awards are conferred in seven programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, The American Business Awards, The International Business Awards, the Stevie Awards for Great Employers, the Stevie Awards for Women in Business and the Stevie Awards for Sales & Customer Service. Stevie Awards competitions receive more than 10,000 entries each year from organizations in more than 60 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. To learn more about the fellow nominees in the "Female Executive of the Year - Consumer Products" category, please visit https://stevieawards.com/women/2016-stevie-award-winners.
About Braeburn Pharmaceuticals
Braeburn Pharmaceuticals, an Apple Tree Partners company, is a commercial-stage pharmaceutical company delivering individualized medicine in neuroscience. Long-acting therapeutic treatment options can be essential to improving patient outcomes and facilitating recovery in neurological and psychiatric disorders, which are often complicated by stigma and present significant public health challenges. Braeburn's commercial product, Probuphine® (buprenorphine) implant was approved by the FDA in May 2016. Braeburn's investigational product pipeline consists of long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia. Braeburn's pipeline products are at various stages of clinical development and include weekly and monthly CAM2038 subcutaneous injection depot formulations of buprenorphine, being investigated in opioid addiction and pain, BB0417 buprenorphine/granisetron injectable for acute pain, and BB0817, six-month risperidone implant being investigated in schizophrenia. More information on Braeburn can be found at www.braeburnpharmaceuticals.com.
Probuphine is the only six-month treatment for opioid dependence that delivers buprenorphine continuously using Titan Pharmaceuticals' (NASDAQ: TTNP) ProNeura™ technology. Probuphine is placed under the skin of the upper arm during an outpatient office procedure and is removed in a similar manner. Probuphine is available through a closed distribution system. To learn more about how to obtain visit: www.braeburnaccessprogram.com. Qualified healthcare providers can register for Probuphine training at www.probuphineREMS.com or by calling 1-866-397-8939. Probuphine is available in all 50 U.S. States; people interested in finding a provider in their area can visit www.probuphinerems.com/probuphine-locator.
Probuphine Indication and Important Safety Information
PROBUPHINE is indicated for the maintenance treatment of opioid dependence in patients who have achieved and sustained prolonged clinical stability on low-to-moderate doses of a transmucosal buprenorphine-containing product (i.e., doses of no more than 8 mg per day of Subutex or Suboxone sublingual tablet or generic equivalent).
PROBUPHINE should be used as part of a complete treatment program to include counseling and psychosocial support.
PROBUPHINE is not appropriate for new entrants to treatment and patients who have not achieved and sustained prolonged clinical stability, while being maintained on buprenorphine 8 mg per day or less of a Subutex or Suboxone sublingual tablet or generic equivalent.
WARNING: IMPLANT MIGRATION, PROTRUSION, EXPULSION and NERVE DAMAGE ASSOCIATED WITH INSERTION and REMOVAL
Risk Associated with Insertion and Removal
Insertion and removal of PROBUPHINE are associated with the risk of implant migration, protrusion, expulsion resulting from the procedure. Rare but serious complications including nerve damage and migration resulting in embolism and death may result from improper insertion of drug implants inserted in the upper arm. Additional complications may include local migration, protrusion and expulsion. Incomplete insertions or infections may lead to protrusion or expulsion.
Because of the risks associated with insertion and removal, PROBUPHINE is available only through a restricted program called the PROBUPHINE REMS Program. All Healthcare Providers must successfully complete a live training program on the insertion and removal procedures and become certified, prior to performing insertions or prescribing PROBUPHINE implants. Patients must be monitored to ensure that PROBUPHINE is removed by a healthcare provider certified to perform insertions.
Please see additional Important Safety Information in the Package Insert that can be found at probuphine.com or by following this link http://probuphinerems.com/wp-content/uploads/2016/02/final-approved-pi.pdf.
Coltrin & Associates on behalf of Braeburn Pharmaceuticals
SOURCE Braeburn Pharmaceuticals